OXABOLONE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H26O3
Molecular Weight	290.3972
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C(O)=C4CC[C@@]23[H]

InChI

InChIKey=GXHBCWCMYVTJOW-YGRHGMIBSA-N

InChI=1S/C18H26O3/c1-18-9-8-11-10-4-6-15(19)17(21)13(10)3-2-12(11)14(18)5-7-16(18)20/h10-12,14,16,20-21H,2-9H2,1H3/t10-,11-,12-,14+,16+,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H26O3
Molecular Weight	290.3972
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://books.google.ru/books?id=afKLA-6wW0oC&pg=PT525&lpg=PT525&dq=steranabol+osteoporosis&source=bl&ots=Me0fhNo13O&sig=wgFxsnNUDN9oJgG1lVXng8vozZc&hl=en&sa=X&ved=0ahUKEwjRx9He-_fOAhVFCywKHV6CBXwQ6AEILTAD#v=onepage&q=steranabol%20osteoporosis&f=false Retrieved from Anabolics By William Llewellyn
Curator's Comment: Description was created based on several sources, including http://pilarmartinescudero.es/EneroFebreroMarzo2014/capillary_investigation_oxabolone_man.pdf and http://www.basskilleronline.com/profile-steranabol.shtml

Oxabolone is a synthetic anabolic steroid. It can be formulated as the cipionate ester prodrug oxabolone cipionate. Oxabolone cypionate is a structural derivative of nandrolone. It differs via the additional 4-hydroxyl group that is attached, therefore making oxabolone cypionate 4-hydroxynandrolone. Oxabolone is on the World Anti-Doping Agency's list of prohibited substances, and is therefore banned from use in most major sports. Oxabolone cypionate is a relatively rare drug that was once produced in Europe for human use. Was used for the treatment of osteoporosis. It is no longer produced by pharmaceutical companies; Upjohn and Pharmacia were the primary producers of it previously.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen Receptor 167 Target ID: CHEMBL1871 Sources: http://www.kegg.jp/entry/D01149	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic hepatitis 9 Sources: http://www.ncbi.nlm.nih.gov/pubmed/1164878	Palliative		Preclinical	Unknown Approved Use Unknown
Osteoporosis 97 Sources: http://www.ndrugs.com/?s=steranabol	Primary		Withdrawn	Steranabol Approved Use Indications: anabolic, osteoporosis, diabetic retinopathy

PubMed

Title	Date	PubMed
Mucosal hyperpigmentation due to oxabolone.	1995 Mar	7604652

Patents

Sample Use Guides

In Vivo Use Guide

The recommended dosage is 100-300 mg/week for about 6-12 weeks

Route of Administration: Intramuscular

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 20:11:19 GMT 2023` Edited by `admin` on `Fri Dec 15 20:11:19 GMT 2023`
Record UNII	51RPF719WE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXABOLONE

Common Name

English

4-HYDROXY-19-NORTESTOSTERONE

Common Name

English

4-HYDROXY NANDROLONE

Common Name

English

ESTR-4-EN-3-ONE, 4,17-DIHYDROXY-, (17.BETA.)-

Systematic Name

English

OXABOLONE [MI]

Common Name

English

Classification Tree Code System Code

DEA NO.

4000